Sorry, you can't buy 381,200 shares at the close without driving the price up by a lot more than a buck. That would suggest that there were that many shares being offered at slightly above the closing price - which is also absurd. That is undoubtedly a bookkeeping entry amalgamating a large series of trades made earlier in the day. We can speculate on the nature of the trades - whether shares were being accumulated or shorted at that point. I suspect a combination of both.
Chemo mills (oncology clinics)are, to my mind, the direct descendants of the 17'th century London houses where they used to dose you with mercury to suppress syphilis. And yes, they will be reluctant to give up their infusion-based thereapies. But it will happen anyway.
You will not be underwater for several years. In fact, six months from now, you will either be substantially ahead or, if it falls, out of the stock altogether. If you really are down by 27 points, it would make sense to harvest part of your loss here, I think, particularly if you have gains elsewhere which you can write it off against. The options suggest a possible move up to 110-115 in January, which would seem to say that the major move won't happen until they get approval for CLL, which should probably be in February (but could come earlier) On the other hand, the fact that the stock has sold off is not necessarily a death warrant. I entered PBYI - cautiously, I thought - at 55, after a major runup, but not at its absolute peak. It fell to 38, where I doubled up, because I still believed in the story. So, on my original shares, after being down over 20% at one point, I an now up about 95%. On the added shares, I'm obviously doing much better than
that. The analysts' price targets for PCYC, which were raised dramatically in previous weeks, are still in place.
Creating the opportunity to sell calls to the doubters.
It seems to me that the word is out about the uptake of Xtandi. This is not a window-dressing stock, since it's basically gone nowhere this year compared to other biotechs.
Yes, but I don't think the current price is based on some wonderful new announcement on Monday. The results in breast cancer already justify the runup, in my opinion. But I think it will fall off toward the close of the session today.
..since I assume that they've been shorting it for the past few hours. Perhaps another one Monday at some point, particularly if they run it up at the open. I bought some for my wife @ 83, got jumpy and sold at about the same price. Now I'm shorting it in her account to see if I can somehow make it up to her ... just a little.
However, the UBS analyst, Roden, raised his price target to 125 yesterday. His comments, as reported on the SA Market Currents page: "Beating Herceptin in a controlled trial (ISPY-2) changes the way that we think about neratanib's potential from being a late-line player in metastatic breast cancer and mutation subgroups to having the potential to compete with high flyers Perjeta and Kadycla in the larger breast cancer segment."
On the Analyst Rating Network, as excerpted on Market Pulse here, I see news of a Stifel upgrade; however, all I can find in the news is the previously announced Stifel downgrade. Puzzling.
They could say that the drug is also producing strong results in areas other than breast cancer, which would make it one of the more important drugs of the decade.
If we didn't hold right now, we'd be giving the feds - and in my case the State of California - a huge Christmas present in return for one day's uncertainty. As for greed, I assume that you're shorting it here - not a bad idea if you cover before Monday PM - and that this speculation is motivated by ........?
We will see by this time tomorrow.
Up only 3 bucks. Other than the hopeful shorts, no one seems to want to sell this stock. At one point this morning,I noted that the bid was 101.22 and the ask was 101.73. If I were short, gaps like that would be disquieting.
All RAD has to do is make enough money to stay in business. Ultimately, either WAG or CVS will have to buy them.
Given California tax law, it's risky to exercise a stock option and not sell the stock. The difference between the exercised price and fair market value is taxable as ordinary income --- which in the higher brackets is about 13%. Plus, for many, a state AMT tax. Yousell the stock to be sure of havingenough profit in the bank to pay the state (and the Feds) their cut.
Yes. The odd thing was how few of the major funds had stakes in this. Adage was buying up sizable chunks,but Baker Brothers Advisors, probably the premier biotech fund, had only a tiny stake. What reassured me was Auerbach's attitude in the analyst presentations, which bordered on arrogant. He certainly didn't waste any time flattering them. The strength of the rally has been remarkable. Continued good luck to you.
The options tell you that this is not possible (the 20 points, not the puppy). However, if we can break back through 100, we should take out some of the shorts' stops, which could be good for a little run.